Singleron Biotechnologies is a pioneering molecular diagnostic company that specializes in applying cutting-edge single cell analysis techniques in clinical diagnosis, drug development, and health management. With a rapidly growing presence in the industry, Singleron offers comprehensive solutions for single-cell sequencing technologies. The company stands out for its commitment to improving clinical diagnosis, drug development, and health management by bringing breakthrough single-cell analysis techniques to clinicians and researchers.

Singleron has established offices, laboratories, and manufacturing facilities in key locations around the world, including Cologne, Germany, Nanjing and Suzhou in China, and New Haven, CT, USA. Singleron has assembled a team of experts with diverse expertise and industry experience. The dedicated leadership, key employees, and technical team bring extensive knowledge in single-cell analysis, genomics, bioinformatics, database construction, and clinical product development.

With an exclusive IP license from Yale University, Singleron has designed and developed the GEXSCOPE® single cell system, which offers a highly suitable single-cell analysis format for clinical applications. The company has obtained over 50 patents and more than 50 software copyrights, showcasing its commitment to innovation and proprietary technologies. Singleron's products include the GEXSCOPE® Single Cell RNA reagents and consumables, enabling parallel RNA-seq library construction from thousands of single cells.

The Singleron Matrix instrument, launched in June 2020, further enhances their product offerings. Singleron collaborates with renowned research institutes, hospitals, and pharmaceutical companies worldwide, driving the adoption of innovative single-cell analysis technologies in clinics and drug discovery. The company's culture revolves around professionalism, high standards, premium quality, expertise, experience, accuracy, innovation, and customer focus.

With a core team of skilled individuals, including the experienced management team, scientific advisory board, and board of directors, Singleron is well-positioned to lead advancements in the field. Leading the charge is Dr. Nan Fang, Chair of the Board and CEO, who has a wealth of experience in product development and commercialization.

Dr. Fang has an accomplished track record, having launched more than 30 products and holds over 20 patents and patent applications. Other key members of the leadership team include Bruno Monschau, General Manager Europe; Andreas Schmidt, Senior Vice President of Global Business Development; Jonathan Scolnick, General Manager Singapore; and Jing Zhou, Co-Founder and Chief Scientific Officer.

Singleron Biotechnologies is dedicated to driving breakthrough applications of single-cell technologies in clinical research and drug development. With its commitment to innovation and focus on precision medicine, Singleron is poised to make a significant impact in the field of molecular diagnostics